Hi everyone, Thank you for participating in the CVC Monthly Meeting last week. Please find below a summary of updates and action items. COVID-19 Terminology SNOMED-CT Codes for COVISHIELD and Janssen COVID-19 vaccine products have been created: COVISHIELD - ConceptID: 28961000087105 - FSN: COVISHIELD 0.5 milliliter solution for injection Verity Pharmaceuticals Inc. (real clinical drug) - PT: COVID-19 COVISHIELD COVID-19 VP Syn: COVISHIELD 0.5 milliliter solution for injection Verity Pharmaceuticals Inc. Janssen (Johnson & Johnson) - ConceptID: 28951000087107 - FSN: JANSSEN COVID-19 0.5 milliliter suspension for injection Janssen Inc. (real clinical drug) - PT: COVID-19 JANSSEN COVID-19 Jan Syn: JANSSEN COVID-19 0.5 milliliter suspension for injection Janssen Inc. These concepts are in scope for the next CVC release and for the March CA Edition publication. Generic agent code: COVID-19 non-replicating viral vector - An RFC has been submitted to Canada Health Infoway to create a generic agent code for COVID-19 non-replicating viral vector vaccines (in which the AstraZeneca, COVISHIELD and Janssen products would fall under). - Link to RFC: https://informs.infoway-inforoute.ca/browse/SCT-11026?filter=-2 - Timeline: a code will be ready before the end of this week. Once it has been created, the CVC team will share with working group members via email and post in the Public Health Surveillance community forum. COVID-19 Pfizer Concept Modifications - Based on published product monograph and discussions with stakeholders, modifications to the COVID-19 Pfizer vaccine concept are as follows: - FSN: PFIZER-BIONTECH COVID-19 messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH - PT: COVID-19 PFIZER-BIONTECH COVID-19 mRNA PB - There were no issues raised by working group members with this change Governance Update - CVC team will share a draft Terms of Reference for the CVC Working Group and for a Clinical Advisory group within two weeks to solicit feedback prior to the next monthly meeting. Next CVC Release - CVC Version 1.1.8 is scheduled to be released on March 5th. Next CVC Meeting - The next CVC Working Group Monthly Meeting will take place on Tuesday, March 30th from 2-3pm EST. Please note that you must register in advance for this meeting (see details below). When: Mar 30, 2021 02:00 PM Eastern Time (US and Canada) Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tJUud-GqrzkiGtXX4o8L9CrP4bXRKwZO0JIe Please let us know if you have any questions, comments or feedback on the above. Best, Taylor

Hi everyone, The meeting agenda for this afternoon's CVC Monthly Meeting has been posted in the Public Health Surveillance community under Documents > Meeting Information > 2021. If you have not already registered and wish to attend the CVC Monthly meeting, please find registration information below. When: Feb 25, 2021 02:00 PM Eastern Time (US and Canada) Register in advance for this meeting: https://infoway-inforoute.zoom.us/meeting/register/tJIuc-Cgqz8tG9J6m9tuM6zKoN5KipKKKpkK

Hi everyone, A SNOMED CT code for the AstraZeneca vaccine has been created: ConceptID: 28761000087108 FSN: ASTRAZENECA COVID-19 0.5 milliliter solution for injection AstraZeneca Canada Inc. (real clinical drug) PT: COVID-19 ASTRAZENECA COVID-19 AZC Syn: ASTRAZENECA COVID-19 0.5 milliliter solution for injection AstraZeneca Canada Inc. This concept is in scope for the next CVC release, and in scope for the SNOMED March CA Edition publication. Update on Generic Concept for AstraZeneca and Janssen Vaccines To expedite the process of creating a code, the AstraZeneca COVID-19 concept has been created under the most generic COVID-19 term (28531000087107 |Vaccine product against disease caused by Severe acute respiratory syndrome coronavirus 2 (medicinal product)|). However, a more granular generic term for both the AstraZeneca and Janssen vaccines is recommended when it becomes available. Based on discussions with clinical subject matter experts (Dr. Sarah Wilson, Public Health Ontario & NACI Member; Dr. Monika Naus, Medical Director, Communicable Diseases & Immunization Service & Medical Head, Immunization Programs & Vaccine Preventable Diseases at the BCCDC) and sources gathered, the AZ and Janssen vaccines are considered "viral vector" vaccines, specifically, "non-replicating viral vector" vaccines. Both use adenoviruses as the viral vector, however, they do not use the same adenovirus vector. There has not been a perceived use case for creating such granular generic concepts at the level of the specific adenovirus. Therefore, we are proposing that the AZ and Janssen vaccines fall under a parent concept, "COVID-19 non-replicating viral vector" vaccine. For a schematic overview and scholarly references for this recommendation, please refer to the PHS Community documents section, under Meeting Information > 2021 > "CVC Working Group - Update on Generic Concept for AstraZeneca and Janssen COVID-19 Vaccines" We have confirmed with Linda Parisien that a generic concept for this does not exist, and have been informed that the SNOMED International community is currently working on developing terminology for this group of vaccines. New concepts for COVID-19 vaccines are anticipated to be available within the coming weeks from SNOMED International. This is also where the COVID-19 mRNA generic concept was drawn from in December. Once an appropriate term becomes available, the CVC will adopt this term as the parent of the AZ and Janssen vaccines, assuming that the concept aligns with the recommendations we have gathered from subject matter experts. Next CVC Release To include the AstraZeneca trade name code, we are proposing to push the next CVC release to next week with the following schedule: - Tuesday, February 16th: Prerelease sent to stakeholders for review - Thursday, February 18th: Deadline to provide feedback - Friday, February 19th: CVC Release Please let me know if you have any questions or concerns with the above.

Hi everyone, Thank you for your participation in last week's CVC meeting. Please find below a summary of the meeting and action items. The next CVC working group meeting is scheduled to take place on Thursday, February 25th from 2-3pm EST. Please note you must register in advance for this meeting via the link below. If you have anything you would like to add to the agenda, please let me know. Register for the CVC Monthly Working Group Meeting: https://infoway-inforoute.zoom.us/meeting/register/tJIuc-Cgqz8tG9J6m9tuM6zKoN5KipKKKpkK 1. Developing a process for new COVID-19 vaccine concepts - The CVC team has received the information needed from Health Canada required to create a trade name concept for the AstraZeneca COVID-19 vaccine, and partial information for the Janssen vaccine. - The CVC team has created a Request For Change for the AstraZeneca vaccine on Informs, which can be found here: https://informs.infoway-inforoute.ca/browse/SCT-10567?filter=-2 (note you must have or register for an account to access this). To be notified of updates to this RFC, select "Watch this issue" on the right-hand side. - Discussion: Are additional generic concepts required to support non mRNA vaccines under review currently? - Action Item: Taylor to consult with stakeholders offline (PHO, CIHI and HC) to determine recommended generic agent codes for adenovirus- vectored vaccines (i.e. Oxford AstraZeneca) - Expected Date of Decision - ASAP - Taylor will seek feedback from CVC committee members prior to next CVC call. - Consensus to draft a letter to ask Health Canada to be a regular advisory member in the work of the CVC. - Action item: CVC team to draft a letter and share with working group members, requesting permission to include organizations as signatories. - Expected date: Taylor will share prior to next CVC call. 2. Proposed additions to HealthCareProviderRoleType subset - There were no objections to adding codes to the HealthCareProviderRoleType subset of the CVC, as they will be administering vaccinations in Ontario. The following codes to be added are: - "PA" - "Physician Assistant" - "PP" - "Paramedic Practitioner" - "PTECH" - "Pharmacy Technician" - "RRT" - "Respiratory Therapist" 3. Data elements & the COVID-19 vaccine rollout - Opened the discussion as to whether additional data elements may be needed in the CVC to meet requirements for national level reporting in the context of COVID-19 - Completion of Vaccination Series (e.g. yes/no) was raised as an element used outside of Canada. - WG members did not perceive a need for adding other data elements at this time. - Beverly to keep the group informed of ISO work that may be relevant for Canada. 4. GS1 Outreach Campaign - GS1 is currently conducting an outreach campaign to vaccine manufacturers to publish GTIN data to the CVC. This campaign could be facilitated with the endorsement of the CVC's end users/contributors. - Action item: CVC team to send a letter to the working group requesting permission to add organization logos to the CVC website. - Expected date - Taylor will share prior to next CVC call. 5. Upcoming releases - Ad-hoc version released on January 28, 2021 with updated lot numbers, including new COVID-19 vaccine lot numbers - February 4th, 2021: Prerelease (version 1.1.8 ) sent to stakeholders for QA - February 11, 2021: Target release (version 1.1.8 )